Skip to main content

Grant Preparation Support

Learn More

Pre-Award Services

Learn More

Pilot Grant Awardees

Learn More

NOTE: UC San Diego's institutional subscription to Pivot will be sunsetting at the end of June 2023. We strongly encourage researchers and administrators to subscribe to UC San Diego Biomedical Funding List for Limited Submission Opportunities announced by UCSD and Foundation Relations for private foundation funding opportunities. You can subscribe to other e-mails lists here.

Here is a list of internal opportunities offered by UC San Diego and the UC system.

Questions? Reach out to us at MCCGrants@health.ucsd.edu

External Grant Opportunities

Federal Sources

Source
Award
Focus Area
Internal Deadline
Sponsor Deadline
Award Amount/Period
Notes
NIH Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional Improve therapeutic development in ultra-rare cancers with high unmet medical need N/A

LOI due date: Feb 19, 2024

Application deadline: April 5, 2024

$500,0000 / year, max. 3 years
NIH
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Advancing and validating emerging cancer-focused technologies
N/A

April 1, 2024

Oct 1, 2024

$300,000 / year, max. 3 years
NIH Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Advancing cancer informatics technologies N/A

June 11, 2024

Nov 15, 2024

$600,000 / year, max. 5 years
NCI The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional) Transitioning mentored cancer researchers to independent faculty positions. N/A

June 12, 2024

Oct 12, 2024 

$100,000 / year for salary $50,000 / year for research, cost max. 3 years
NIH PAR-22-136: Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Training for clinician-scientists (MD, DO, PharmD, nurses with PhD) N/A June 17, 2024 $50,000-Year 1, $750,000-Years 2-5
NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) Research in cancer control and population sciences N/A

July 5, 2024

Oct 5, 2024

$250,000 / year / max. 5 years
NIH

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

Potential to reduce cancer burden N/A

June 5, 2024

Oct 5, 2024

Budget not limited / max. 5 years
NIH Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 or U01; Clinical Trial Optional) Incorporate a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program N/A

April 1, 2024

Oct 1, 2024 

$150,000 / year / max. 2 years
NIH

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

R21 companion us available here.

Informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum N/A
Jun 11, 2024
Nov 15, 2024
Budget not limited / max. 5 years
NIH

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)

Address challenges in cancer and cancer disparities research, education, and outreach, as well as cancer's impact on underserved populations N/A
Oct 9, 2024
Oct 9, 2025
$1.7 - 2.2 million / max. 5 years
NCI

NCI’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)

Cancer-targeted diagnostic and therapeutic interventions N/A

June 5, 2024

Oct 5, 2024

$499,999 / year / max. 5 years
NIH

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment N/A

 

June 10, 2024

Oct 8, 2024 

$250,000 - $275,000
NIH

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)

Support New Investigators and Early Stage Investigators (ESIs) from diverse backgrounds N/A

 

June 18, 2024

Nov 19, 2024

$275,000 / 2 years / max. 2 years
NIH

Advancing Genomic Medicine Research (R01 Clinical Trial Optional)

Implement the use and sharing of genomic information and technologies in clinical care N/A

 

July 8, 2024

Feb 11, 2025

$500,000 / year / max. 5 years

NIH

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)

Prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers N/A

 

May 25, 2024

Sept 25, 2024

Jan 25, 2025

$1.4 million / per year / max. 5 years
NIH

Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)

Support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs N/A

 

May 25, 2024
Sept 25, 2024
Jan 25, 2025
$300,000 / per year / 5 years

Non-Federal Sources

Source
Award
Focus Area
Internal Deadline
Sponsor Deadline
Award Amount/Period
Notes
Cancer-related health disparities in underserved populations
N/A
2 April 2024
$250,000 / 1 year
Cancer prevention, detection, or treatment
N/A
2 April 2024
$250,000 / 1 year
Collaborative cancer research
N/A
2 April 2024
$250,000 / 1 year
Translational pojects for advancing to pre-clinical or clinical stages
N/A
14 May 2024
$500,000 / 1 year
Innovative ground-breaking ideas intended to change the course of cancer research and care
N/A
14 May 2024
$1,000,000 / multiple years
Tackle challenges in the prevention, diagnosis, and treatment of cancer
N/A
12 March 2024
$3,000,000 / 3 years
Mark Foundation
High-impact, high-risk projects
N/A
29 April 2024
$750,000 / 3 years
Adult cancer
March 8, 2024
April 19, 2024
$800,000
MCC Limited Submission
Bristol Myers Squibb
Research and translation of cancer immunotherapy
N/A
April 1, 2024
$200,000 / 2 years
Melanoma Research Alliance
Research in cancer immunotherapy for the treatment of patients with melanoma
N/A
April 1, 2024
$200,000 / 2 years
MERCK
Cancer immunotherapy research and translational immunotherapeutic approaches
N/A
April 1, 2024
$100,000 / 1 year
SITC
Clinical or translational research in cancer immunotherapy
N/A
April 1, 2024
$100,000 / 1 year
Mallinckrodt Pharmaceuticals
Research and translation of adverse events in cancer immunotherapy.
N/A
April 1, 2024
$40,000 / 1 year

Internal Grant Opportunities

Award
Focus Area
Deadline
Award Amount/Period
Notes
2024 HWSPH and MCC Pilot Project Grants Public health and cancer control

March 18, 2024

5 p.m.

$15,000 - $30,000